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Dynamic expression of HOPX in 
alveolar epithelial cells reflects 
injury and repair during the 
progression of pulmonary fibrosis
Chiharu Ota1,2, John-Poul Ng-Blichfeldt3, Martina Korfei4, Hani N. Alsafadi  1,  
Mareike Lehmann1, Wioletta Skronska-Wasek1, Martina M. De Santis  1, 
Andreas Guenther4,5, Darcy E. Wagner  1,6 & Melanie Königshoff1,7
Mechanisms of injury and repair in alveolar epithelial cells (AECs) are critically involved in the 
progression of various lung diseases including idiopathic pulmonary fibrosis (IPF). Homeobox only 
protein x (HOPX) contributes to the formation of distal lung during development. In adult lung, alveolar 
epithelial type (AT) I cells express HOPX and lineage-labeled Hopx+ cells give rise to both ATI and ATII 
cells after pneumonectomy. However, the cell function of HOPX-expressing cells in adult fibrotic lung 
diseases has not been investigated. In this study, we have established a flow cytometry-based method 
to evaluate HOPX-expressing cells in the lung. HOPX expression in cultured ATII cells increased over 
culture time, which was accompanied by a decrease of proSP-C, an ATII marker. Moreover, HOPX 
expression was increased in AECs from bleomycin-instilled mouse lungs in vivo. Small interfering RNA-
based knockdown of Hopx resulted in suppressing ATII-ATI trans-differentiation and activating cellular 
proliferation in vitro. In IPF lungs, HOPX expression was decreased in whole lungs and significantly 
correlated to a decline in lung function and progression of IPF. In conclusion, HOPX is upregulated 
during early alveolar injury and repair process in the lung. Decreased HOPX expression might contribute 
to failed regenerative processes in end-stage IPF lungs.
The lung is a complex organ which is directly exposed to numerous external stimuli, such as cigarette smoke, 
pathogens, air pollution, or particles from the environment1. The distal lung is composed of alveoli which are 
covered by alveolar epithelial type (AT) I cells and ATII cells. ATI cells are squamous, large, and flat cells, which 
cover 95% of the internal surface area of the alveoli2. ATI cells play an indispensable role for gas exchange and 
alveolar-capillary barrier function2. Thus, it is critically important to preserve and regenerate ATI cells for proper 
respiratory function. ATII cells maintain alveolar homeostasis as a “caretaker” of alveoli3 to produce and secrete 
surfactant proteins4, to keep the fluid balance of the alveoli5, and to serve as progenitor cells for ATI/ATII cells 
during lung turnover and repair6. Mechanisms of alveolar epithelial injury and repair have been proposed to be 
critically involved in the progression of various lung diseases, including idiopathic pulmonary fibrosis (IPF), a 
fatal interstitial lung disease1.
Homeobox only protein x (HOPX) is a Homeobox protein important for anterior-posterior patterning dur-
ing organ development7,8. In the developing lung, HOPX contributes to the formation of distal lung9. In adult 
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murine lung, ATI cells express HOPX10 and lineage-labeled Hopx+ cells, which are further positive for ATI cell 
markers, give rise to both ATI and ATII cells after pneumonectomy11. Thus, HOPX might be involved in the 
bidirectional trans-differentiation of ATII to ATI or ATI to ATII during adult alveolar repair. It is also known 
that HOPX-expressing cells serve as stem cells in intestinal epithelium12 or hair follicle13. Furthermore, HOPX is 
further described as a tumor suppressor gene in the lung that regulates cellular proliferation and metastasis14,15. 
However, the function of HOPX-expressing cells in the adult fibrotic lung has not yet been clarified. In the pres-
ent study, we aimed to gain a detailed insight into the dynamics of HOPX-expressing alveolar epithelial cells 
(AECs) during lung injury and repair and established a flow cytometry (FCM)-based method to quantify the 
HOPX-expressing cells in AECs. We then investigated HOPX expression in an ATII-ATI trans-differentiation 
culture model in vitro, in bleomycin-induced mouse model of pulmonary fibrosis in vivo, and by database analy-
ses of expression profiles of IPF lungs in silico.
Results
ProSP-C and HOPX expression during ATII-ATI trans-differentiation. To investigate the potential 
role of HOPX in adult lung injury/repair, we first investigated the changes of HOPX expression in primary mouse 
(pm) ATII cells (95+/−3% of proSP-C expression) from wildtype mice during 2D-culture in vitro. This in vitro 
culture system is well-established to study trans-differentiation of ATII cells into ATI-like cells16–18, a process 
known to be implicated in lung repair. Hopx expression was increased (Fig. 1A) over 5 days of culture along 
with decreased Sftpc expression, as evaluated by qRT-PCR (Fig. 1B) and FCM (Fig. 1C and D, mean fluorescent 
intensity (MFI) for Fig. 1E), which is consistent with previous reports10,16. Moreover, after an initial increase, the 
proliferation marker Mki67 was decreased during the time course (Fig. 1F). We next optimized the FCM-based 
quantification of HOPX expression in pmATII cells using the same trans-differentiation system (Fig. 1G,H). 
Figure 1. Expression of HOPX and proSP-C during ATII-ATI cell trans-differentiation in vitro. Quantitative 
(q) RT-PCR analysis of (A) Hopx (B) Sftpc, (C,D) FCM analysis of proSP-C expression over culture, (E) mean 
fluorescent intensity (MFI) of proSP-C-Alexa-fluor 488, and (F) qRT-PCR analysis of Mki67 during 5 days 
culture of pmATII cells (n = 3). (G,H) FCM-based quantification of HOPX expression during the culture. 
(I) and (J) FCM-based quantification of HOPX/proSP-C co-expression during the culture (n = 3). *p < 0.05, 
**p < 0.01, ***p < 0.005.
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HOPX expression was gradually increased during the culture (Fig. 1H). In addition, we evaluated the co-ex-
pression of proSP-C and HOPX within freshly isolated pmATII cells over culture time (Fig. 1I). We found that 
HOPX+/proSP-C+ cells as well as HOPX+/proSP-C− cells were increased while HOPX−/proSP-C+ cells were 
decreased during trans-differentiation (Fig. 1J).
HOPX expression was increased in the alveolar epithelium in bleomycin (BLM)-instilled 
lungs. Disturbed ATII to ATI cell trans-differentiation has been linked to lung fibrosis16,17. Thus, we next 
sought to investigate the expression changes of HOPX in fibrotic lung diseases using the FCM analysis. We eval-
uated Hopx expression in the mouse model of pulmonary fibrosis induced by intra-tracheal BLM instillation. We 
isolated ATII cells from phosphate buffered saline (PBS)-instilled lungs (PBS-pmATII cells) as a control group 
and BLM-instilled mouse lungs (BLM-pmATII cells) after 14 days of the initial PBS/BLM instillation. We found 
that mRNA expression of Hopx (Fig. 2A) and T1α (Fig. 2B) was significantly upregulated whereas Sftpc (Fig. 2C) 
was significantly downregulated in BLM-pmATII cells compared with PBS-pmATII cells. Next, we evaluated the 
expression of proSP-C and HOPX by FCM (Fig. 2D). Quantification of the FCM analysis revealed a significant 
decrease of HOPX−/proSP-C+ cells while HOPX+/proSP-C+ cells were significantly increased in BLM-pmATII 
cells compared to in PBS-pmATII cells (Fig. 2E). Importantly, further immunofluorescence (IF) also revealed that 
HOPX expression was increased in BLM-instilled lungs compared with PBS-instilled lungs in situ (Fig. 2F and G). 
The cells which co-expressed both HOPX and proSP-C were increased in BLM-lungs (Fig. 2G, shown in white 
arrows, and Fig. 2I, shown in green dots) compared to PBS-lungs (Fig. 2F and H). The co-expression of proSP-C 
and HOPX was also confirmed by IF of cytospun pmATIIs which were freshly isolated from PBS- (Fig. 2J) or 
BLM-instilled lungs (Fig. 2K).
HOPX knockdown activated cellular proliferation. To investigate whether HOPX is involved in the 
proliferation of lung epithelial cells, we silenced Hopx by siRNA in the murine alveolar epithelial cell line MLE12, 
which endogenously expresses HOPX. We found that HOPX/Hopx expression was efficiently reduced in the 
cells as assessed by qRT-PCR (Fig. 3A) and western blotting (Fig. 3B, quantification in Fig. 3C). Next, we per-
formed an EdU-based proliferation assay using the siRNA-transfected MLE12 cells with co-staining of HOPX 
by FCM. We found that Hopx knockdown (siHopx) increased the HOPX−/EdU+ population while reducing the 
HOPX+/EdU+ population (Fig. 3D,E). Further, we observed an increase in proliferation using a scratch assay 
in siHopx-transfected MLE12 cells (Fig. 3F,G). In support of these observations, we found that the knockdown 
of Hopx significantly increased Mki67 expression as well as ATII marker Sftpc (Fig. 3H and I), and increased net 
metabolic activity as assessed by WST1 assay (Fig. 3J). In addition, we evaluated Ki67+ cells with and without 
HOPX in the BLM-instilled lung by IF. The number of Ki67+ cells within the HOPX+ fraction was significantly 
lower than that within the HOPX- fraction (Fig. 3K). Altogether, these results suggest that HOPX is involved in 
suppression of AEC proliferation.
HOPX expression in IPF lungs. Thus far, we have shown that HOPX contributes to adult lung injury/
repair process in mouse lungs. Next, we sought to clarify whether HOPX might act as a modulator of lung injury/
repair in human lungs. To this end, we first analyzed microarray datasets in silico to investigate the expression 
changes of HOPX in IPF lungs. In contrast to the mouse data, we found that HOPX expression was significantly 
decreased in whole lung homogenate from IPF lungs compared with control lungs (Fig. 4A) and the lung func-
tion parameter DLCO was significantly correlated with HOPX expression (Fig. 4B), as indicated in the dataset 
from Lung Genomics Research Consortium (LGRC) (Gene Expression Omnibus Series (GSE) accession number: 
47460; National Center for Biotechnology Information, Bethesda, MD, USA; https:// www. ncbi. nlm. nih. gov/ 
geo/). As shown in Fig. 4C by the expression of matrix metalloprotease (MMP7), a biomarker for progression of 
IPF19, HOPX expression was significantly lower in later stage than in earlier stage. Next, we confirmed decreased 
expression of HOPX (Fig. 4D) and SFTPC (Fig. 4E) transcripts in our own cohort (lung tissue from IPF explant 
and Donor lungs), while ACTA2, a mesenchymal marker, was increased (Fig. 4F).
Next, we stained serial lung tissue sections of organ donor and IPF patients’ lungs with cytokeratin 5 (KRT5, 
a marker for airway basal cells), proSP-C, HOPX, and cytokeratin 7 (KRT7, a marker for general epithelia), and 
Ki67, to show the expression pattern of HOPX and proSP-C as well as their proliferation status in IPF lungs 
(Fig. 4G and H). In IPF, KRT7+ cells are more abundant than in control lungs as previously shown in the study 
from our laboratory20. We observed that proSP-C+/KRT7+ cells of IPF lungs frequently exhibited an intense 
expression of HOPX without nuclear Ki67 expression (arrows in panel 1–4 in Fig. 4G). Whereas proSP-C+/
KRT7+ cells without HOPX positivity were often observed within preserved alveolar septae (white arrowheads 
in panel 5, Fig. 4G), proSP-C+/KRT7+ cells within fibrotic regions were mostly HOPX positive (black arrows, 
Fig. 4G).
In addition, proSP-Clow/KRT7+ AECs of IPF lungs also exhibited robust HOPX immunoreactivity with 
nuclear Ki67 expression (asterisks in panels 2 and 4 in Fig. 4G). Finally, KRT5+/KRT7+ basal cells in abnor-
mal bronchiolar structures of IPF lungs did not express HOPX, and exhibited strong nuclear expression of Ki67 
(panel 2 in Fig. 4G, indicated by black arrowheads). The data suggest that in the fibrotic area, there are HOPX+/
proSP-C+/KRT7+ cells, HOPX+/proSP-Clow/−/KRT7+ cells, and HOPX−/proSP-C+/KRT7+ cells as observed in 
the BLM-instilled mouse lungs. Intriguingly, HOPX+/proSP-C+/KRT7+ cells and HOPX+/proSP-Clow/−/KRT7+ 
cells were less in the donor lungs and preserved alveolar septa, compared to fibrotic area, as observed in the BLM 
lungs. In addition, there are few HOPX−/proSP-C+/KRT7+ cells in the fibrotic area.
To further corroborate our immunohistochemistry study, we analyzed a recently published single cell RNA 
sequence analysis of EpCAM+/HTII280+ cells from control and IPF patients’ lungs21. Importantly, EpCAM+/
HTII280+ cells from IPF patients exhibited decreased HOPX (Fig. 4I) and SFTPC expression (Fig. 4J), 
and increased expression of KRT7 (Fig. 4K). Furthermore, CTNNB1 (Fig. 4L) and CCND1 (Fig. 4M) were 
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Figure 2. Expression of HOPX/proSP-C lung epithelial cell subpopulations in BLM-induced pulmonary 
fibrosis model in vivo. Quantitative RT-PCR analysis of (A) Hopx (B) T1α, and (C) Sftpc in EpCAM+ cells 
from PBS or BLM-instilled lungs (n = 4). (D) FCM-based evaluation of HOPX/proSP-C expression in pmATII 
cells from PBS or BLM-instilled lungs (representative images from n = 3). Quantification of (E) HOPX−/
proSP-C+, HOPX+/proSP-C−, and HOPX+/proSP-C+ cells in PBS and BLM-instilled lungs (n = 3). 
Immunofluorescence staining (IF) of HOPX (white) and proSP-C (red) in the sections from (F) PBS and (G) 
BLM-instilled lungs. Visualization of the co-expression of HOPX and proSP-C from (H) PBS and (I) BLM-
instilled lungs using ZEN2009 software. IF of HOPX (white) and proSP-C (red) in cytospun EpCAM+ cells 
from (J) PBS and (K) BLM-instilled lungs. *p < 0.05, **p < 0.01, ***p < 0.005.
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significantly upregulated in EpCAM+/HTII280+ cells from IPF lungs. These data further support the idea that 
decreased HOPX expression in IPF contributes to failure of AEC regeneration and excessive/aberrant epithelial 
proliferation.
Discussion
Temporal and spatial heterogeneity is one of the histological characteristics of IPF. Several stages of IPF, including 
initiation, progression, and the terminal stage of the disease, exist at the same time in the same lung. This hetero-
geneity suggests an ongoing dynamic process with different stages of alveolar injury, repair, and failed regenera-
tion. There are various reported biomarkers of IPF22. Of these, serum levels of surfactant protein A (SP-A) and D 
(SP-D), which are synthesized and secreted by ATII, have been reported to predict mortality23, exacerbation24, or 
progression25 of IPF. The increase of these ATII-associated proteins may reflect alveolar dysfunction induced by 
Figure 3. Effect of HOPX on proliferation and differentiation in MLE12 epithelial cells in vitro. Evaluation of si-
RNA-based Hopx knockdown in MLE12 lung epithelial cells with (A) qRT-PCR of Hopx, (B) Western blotting 
of HOPX, (C) quantification of Western blotting data. (D) EdU assay of MLE12 lung epithelial cells co-stained 
with HOPX antibody in vitro. Alexa Fluor 647-EdU+ cells and Alexa Fluor 488-HOPX+ cells were evaluated 
by FCM (Representative image of n = 2). (E) Quantification of HOPX+ EdU+ cells and HOPX-EdU+ cells in 
MLE12 cells (n = 2). (F,G) Cellular scratch assay, qRT-PCR analysis of (H) Mki67 and (I) Sftpc, and (J) WST 
assay of MLE12 cells transfected with control siRNA and Hopx siRNA. (J) The ratio of Ki67 positive/negative 
cells with HOPX co-expression in IF. *p < 0.05, **p < 0.01, ***p < 0.005.
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Figure 4. Expression and localization of HOPX in control (donor) and IPF lungs. In silico analysis from Lung 
Genomics Research Consortium (LGRC) of (A) HOPX mRNA expression in organ donor (control) and IPF 
lungs, (B) correlation between HOPX mRNA expression and DLco (blue dots: control, red dots: IPF). (C) 
Correlation between HOPX mRNA and MMP7 mRNA in control (blue dots) and IPF (red dots) in silico. QRT-
PCR analysis of (D) HOPX mRNA, (E) SFTPC mRNA, and (F) ACTA2 mRNA from whole lung homogenate 
of control and IPF lungs in our cohort. (G) Immunohistochemical staining of serial sections of control and 
IPF lung tissue for KRT5, proSP-C, HOPX, KRT7, and Ki67. In IPF lungs, proSP-C+/KRT7+ cells revealed 
cytoplasmic or in part nuclear expression of HOPX without nuclear Ki67 (Indicated by arrows in panels 
1–4). ProSP-Clow/KRT7+ AECs of IPF-lungs also indicated robust HOPX-immunoreactivity with nuclear 
Ki67 expression (asterisks in panel 2 and 4). Some proSP-C+/KRT7+ cells without HOPX immunoreactivity 
were observed in the area of relatively preserved alveolar septa (white arrowheads in panel 5). KRT5+/KRT7+ 
bronchiolar basal cells did not express HOPX, and indicated nuclear expression of Ki67 (Indicated by black 
arrowheads in panel 2). (H) Immunohistochemical staining of serial sections of control donor lung tissues 
for KRT5, proSP-C, HOPX, KRT7, and Ki67. In donor lungs, HOPX expression was present in proSP-C+/
KRT7+ ATII (arrows) and proSP-Clow/KRT7+ AECs (asterisks) (panels 2 and 3 in Fig. 4O), and faint in normal 
bronchiolar epithelium. ProSP-Clow/KRT7+ AECs expressing HOPX also revealed nuclear Ki67 expression 
(indicated by asterisks). In silico single cell RNA sequence analysis of (I) HOPX, (J) SFTPC, (K) KRT7, (L) 
CTNNB1, and (M) CTND1 in EpCAM+/HTII280+ cells. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001.
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alveolar injury processes in IPF. On the other hand, MMP7 and MMP1, which degrade extracellular matrix, are 
increased in plasma from IPF patients. The increase of MMPs may reflect the excessive tissue repair and remode-
ling22,26. We showed that HOPX is increased in relatively early injury and decreases along with the progression of 
the disease. In the present study, HOPX is shown to be upregulated in pmATII cells in BLM model of pulmonary 
fibrosis in vivo. In contrast, we found that HOPX mRNA was decreased in whole lung homogenate and human 
EpCAM+/HTII280+ cells from end-stage IPF lungs. These results may be explained by several potential areas 
which warrant further study. BLM lung injury is known to not fully recapitulate all aspects of clinical IPF and 
may represent a relatively “early” time point of regeneration in alveolar epithelium after injury whereas analyzed 
IPF patient samples derived from explants represent rather later disease stages. It is well-known that animals can 
recover and regenerate in the BLM model of fibrosis when the level of injury is not too severe. Our data allow the 
hypothesis that at the initial stage of regeneration, expression of HOPX is still low to allow ATII cells to undergo 
self-renewal, whereas at the later stage, HOPX-expressing cells are increased to suppress the aberrant/excessive 
proliferation and remodeling of alveoli. Thus, it is entirely plausible that a HOPX-expressing population survived 
the initial injury and participates in epithelial regeneration. It will be interesting in future studies to explore 
the levels of HOPX in different fibrotic animal models (e.g. adeno-TGF-β27) or models with varying degrees of 
severity. Importantly, we recently observed loss of HOPX in an ex vivo human tissue model of early IPF using pre-
cision cut lung slices28, and while HOPX expression increased in BLM-derived pmATII cells, human EpCAM+/
HTII280+ cells in IPF lungs decreased21. These findings support the hypothesis that EpCAM+/HTII280+ cells 
in IPF have already lost their regenerative capability, while pmATII cells in BLM might still exhibit regenerative 
capacity in the relatively “early” repair period. Taken together, HOPX may be a marker for the extent of alveolar 
injury or a marker of the progression of repair, and failed regeneration.
Using the FCM-based technique and IF, we describe 3 different AEC phenotypes in terms of HOPX and 
proSP-C expression in murine and human alveolar epithelial cells: HOPX−/proSP-C+ ATII cells, HOPX+/
proSP-C− ATI cells, and HOPX+/proSP-C+ AECs. Of note, we observed an increase in the number of HOPX+/
proSP-C+ cells in both BLM-treated mouse lungs and human IPF lungs. These HOPX+/proSP-C+ AECs could 
be intermediate cell types between ATII-ATI during trans-differentiation, or bipotent progenitor cells capable 
to differentiate either ATII or ATI cells, which have been described in the developing lung29 and also in alveolar 
epithelial progenitor lineage from adult human lung in the recent study30. Our data support the notion that either 
intermediate or bipotent progenitor cell type could emerge during alveolar injury and repair process.
HOPX is also known to be a tumor suppressor gene in several organs31–34. In the lung, HOPX expression 
inhibited lung adenocarcinoma formation and metastasis14,15. In our study, we demonstrate that HOPX is 
involved in suppression of epithelial cell proliferation in vitro. IHC on IPF lungs also indicated that HOPX+/
proSP-C+/KRT7+ AECs lacked nuclear Ki67 expression. In addition, KRT5+/proSP-C−/HOPX−/KRT7+ abnor-
mal bronchiolar basal cells in IPF showed more nuclear Ki67 expression. End-stage IPF lungs indicate fibrotic 
scarring as well as increased bronchiolization, i. e. enhanced bronchiolar proliferation and replacement of alveoli 
by bronchiolar epithelium, HOPX expression may decrease during this process along with the progression of IPF.
In IPF, alveolar epithelial regeneration is incomplete or ineffective35. This may be due to the persistence of 
“repetitive triggers” caused by genetic susceptibility36–39 or epigenetic changes40,41, resulting in permanent and 
persistent epithelial injury and apoptosis42. In a variety of studies, “maladaptive” pro-apoptotic endoplasmic retic-
ulum stress, DNA damage as well as senescence have been well documented in the AECII of patients with spo-
radic and familial IPF20,43. These conditions might be responsible for the reduction of genes involved in alveolar 
maintenance, such as HOPX. In addition, IPF is characterized by a “hyper-responsive” regenerative loop due to 
re-activation of developmental pathways including sonic hedgehog44, TGF-β45, and Wnt signaling46, resulting in 
inappropriate proliferation of alveolar epithelial precursors, which are also prone to die due to replicative senes-
cence, and presumably also due to loss of HOPX. Impaired alveolar regeneration in IPF is paralleled by the abnor-
mal proliferation of bronchiolar basal cells, which initiate bronchiolization, leading to the migration and invasion 
of these bronchiolar progenitors into distal alveolar spaces, and finally replacement of alveoli. Indeed, bronchiolar 
basal cells which do not express HOPX, can be found in abnormal luminal position directly near ATII in alveoli47. 
Therefore, we suggest that the loss of HOPX due to increased bronchiolization of alveoli aggravate the impaired 
alveolar regeneration. Our data support the hypothesis that HOPX expression maintains AEC quiescence during 
alveolar homeostasis, whereas HOPX induction limits aberrant AEC proliferation during normal lung injury/
repair. Furthermore, aberrant HOPX expression may contribute to increased alveolar senescence in IPF.
Conclusion
HOPX contributes to alveolar injury/repair process in fibrotic lung diseases, but fails to regenerate alveolar epi-
thelium in IPF, due to loss of HOPX. HOPX may thus be potential indicator of the progression of fibrosis.
Methods
Human Samples. The study protocol was approved by the Ethics Committee of the Justus-Liebig-University 
Giessen (No. 111/08 and 58/15), and informed consent was obtained in written form from each subject. All IPF 
diagnoses were made on the basis of the recent IPF consensus guidelines48 and a usual interstitial pneumonia 
(UIP) pattern was consistently observed in all used lung tissues. All methods, including those involving human 
samples, were performed in accordance with the relevant guidelines and regulations.
Animals. Six to eight-week-old female wildtype C57/BL6N mice were obtained from Charles River and 
housed in rooms with constant humidity and temperature with 12 h light cycles and free access to water and 
rodent chow. All animal studies were performed under the strict governmental and international guidelines and 
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approved by the local government for the administrative region of Upper Bavaria (Project 55.2-1-54-2532-88-12). 
All methods were performed in accordance with the relevant guidelines and regulations.
Isolation and culture of primary mouse AECs. Primary mouse (pm) ATII cells were isolated as pre-
viously described with some modifications49. Briefly, lungs were perfused with ice-cold phosphate buffer saline 
(PBS) (Invitrogen, Thermo Fischer Scientific, Waltham, MA USA) via right ventricle. Then dispase (Roche Applied 
Science, Mannheim, Germany) and agarose (low gelling temperature) (Sigma Aldrich, St. Louis, MO, USA) were 
intratracheally instilled into the mouse lungs. CD45 positive white blood cells were magnetically depleted by CD45 
microbeads (Miltenyi Biotec, Teterow, Germany) and pmATII cells were magnetically isolated by epithelial cell 
adhesion molecule (EpCAM) microbeads (Miltenyi Biotec). pmAECs were cultured on plastic plates with DMEM/
F12 medium supplemented with 10% fetal bovine serum (FBS, Invitrogen, Thermo Fischer Scientific), 100 mg/l 
streptomycin, and 100 U/ml penicillin (Sigma Adrich) for 5 days and harvested on days 2, 3 and 5.
Evaluation of HOPX and proSP-C expressing cells by flow cytometry. HOPX and proSP-C expres-
sion within epithelial cells was evaluated by flow cytometry (FCM). Magnetically-isolated cells were fixed and 
permeabilized with IntraPrepTM Permeabilization Reagent (Beckman Coulter, Brea, CA, USA) and stained with 
HOPX mouse monoclonal antibody (sc-398703, 1:200, Santa Cruz Biotechnology, Dallas, TX, USA) and proSP-C 
rabbit polyclonal antibody (1:1000, Merck Millipore, Billerica, MA, USA). Normal mouse IgG (Santa Cruz 
Biotechnology) and rabbit serum (Life Technologies Corp.) were used for the isotype controls. Alexa Fluor 647 
goat anti-mouse IgG and Alexa Fluor 488 goat anti-rabbit IgG (Life Technologies Corp.) were used for secondary 
antibodies. Intracellular expression of HOPX and proSP-C was detected using a FACS LSR II flow cytometer (BD 
Biosciences, San Jose, CA, USA). The HOPX and pro-SP-C positive populations were quantified by FlowJo soft-
ware (Tomy Degital Biology Co., Ltd., Tokyo, Japan).
HOPX expression in bleomycin-induced lung injury/repair model. Eight-week-old female wildtype 
C57/BL6N mice were instilled with PBS or 2 units (as a single dose of 2 U/kg body weight in 50 µl PBS) of bleo-
mycin (BLM, Bleomycin sulfate, Almirall, Barcelona, Spain) in vivo. After 14 days of instillation, fixed lung tissue 
was used for IF. pmATII cells from PBS/BLM mouse lungs were separated as above and the cells were used for 
quantitative (q) RT-PCR and FCM analysis.
Hopx siRNA transfection. Murine lung epithelial cells (MLE12) were purchased from ATCC (CRL-2110) 
and cultured in RPMI medium (Invitrogen, Thermo Fischer Scientific) supplemented with 10%FBS, 100 mg/l 
streptomycin, and 100 U/ml penicillin.MLE12 cells were grown until 70–80% confluency in six-well cluster plates 
and transfected with 150 pmol/l of specific double-stranded siRNA targeted against the Hopx transcript (sc-
38672; Santa Cruz Biotechnology, Inc.) in serum-free Opti-MEM medium (Life Technologies) in combination 
with Lipofectamine 2000 transfection reagent (Life Technologies). Control transfections were performed using 
150 pmol/l non-silencing control siRNA (SC-37007; Santa Cruz Biotechnology,Inc.). After 24 h of transfection, 
the cells were collected for RNA isolation, metabolic assay, FCM analysis, or lysed for western blotting.
WST-1 metabolic assay. WST-1 metabolic assay was performed as previously described50.
EdU assay. EdU-based proliferation assay was performed using Click-iT® EdU Alexa Fluor® 647 Imaging Kit 
(Invitrogen, Thermo Fischer Scientific) as manufacturer’s instructions with some modifications. Briefly, MLE12 
cells were incubated with EdU solution for 24 hours, fixed with 3.7% formaldehyde, and permeabilized with 0.5% 
TritonX-100. Then the cells were intracellularly stained with mouse HOPX antibody as described above. Alexa 
Fluor 647 secondary dye was used to visualize EdU positive cells and Alexa Fluor 488 goat anti-mouse IgG was 
used to evaluate HOPX expression. The number of EdU positive/HOPX positive, or EdU positive/HOPX negative 
cells were measured and quantified by a FACS LSR II flow cytometer (BD Biosciences).
Scratch assay. Scratch assay was performed using Culture-Insert 2 well in μ-Dish 35 mm (Nippon Genetics 
Co. Ltd., Tokyo, Japan) according to the manufacturer’s instructions. The gap between the cells were measured 
using ImageJ software (from NIH, MD, USA).
Total RNA isolation and qRT-PCR. Total RNA from pmAECs and whole lung homogenate was isolated 
using Total RNA Kit, peqGOLD (VWR International, Radnor, PA, USA) according to the manufacturer’s instruc-
tions. cDNA was synthetized as previously described28. QRT-PCR was performed using SYBR green and the 
LightCycler 480 system (Roche, Mannheim, Germany). Expression changes of alveolar epithelial genes (Hopx, 
Sftpc, T1α), proliferation markers (Mki67, Ctnnb1) were evaluated by qRT-PCR. Primer sequences were as fol-
lows; mHopx forward: 5′TCTCCATCCTTAGTCAGACGC3′, reverse: 5′GGGTGCTTGTTGACCTTGTT3′, 
mSftpc forward: 5′AGCAAAGAGGTCCTGATGGA3′, reverse: 5′GAGCAGAGCCCCTACAATCA 3′, mT1α 
forward: 5′ACAGGTGCTACTGGAGGGCTT3′, reverse: 5′TCCTCTAAGGGAGGCTTCGTC3′, mHprt: 5′ 
CCTAAGATGAGCGCAAGTTGAA3′, 5′ CCACAGGACTAGAACACCTGCTAA3′.
Immunofluorescence staining. Immunofluorescence staining (IF) of the lung sections was performed as 
previously described49 with some modifications. Briefly, after deparaffinized, the lung sections were boiled in cit-
rate buffer (10 mM Citric Acid, pH 6.0) for 10 minutes at 90 °C to retrieve antigens. Samples were blocked by 5% 
BSA with 0.1% TritonX-100 (company) in PBS for 2 hours at room temperature, and then stained with primary 
antibodies overnight at 4 °C. We used the following primary antibodies; HOPX mouse monoclonal antibody 
(1:200, Santa Cruz Inc., sc-398703) and proSP-C rabbit polyclonal antibody (1:1000, Merck Millipore, Billerica, 
MA, USA, AB3786). Normal mouse IgG (Santa Cruz Biotechnology) and rabbit serum (Life Technologies Corp.) 
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were used for the isotype controls. Alexa Fluor 647 goat anti-mouse IgG and Alexa Fluor 488 goat anti-rabbit IgG 
(Life Technologies Corp.) were used for secondary antibodies. On the following day, the sections were washed 
with 1% BSA/PBS and stained with secondary antibodies for 1 hour at room temperature. Samples were visual-
ized using a Zeiss LSM710 confocal microscope (Carl Zeiss, Oberkochen, Germany). Images were obtained, and 
co-localization analysis was performed with ZEN2009 software (Carl Zeiss).
Immunohistochemistry. Immunohistochemistry (IHC) of the lung sections was performed as previously 
described in detail20. The primary antibodies used for IHC are listed as follows: proSP-C rabbit polyclonal anti-
body (1:750, Merck Millipore, AB3786), rabbit monoclonal antibody for human cytokeratin-5 (KRT5) (1:200, 
Abcam, Cambridge, United Kingdom, ab75869), rabbit monoclonal antibody for human cytokeratin-7 (KRT7) 
(1:200, Abcam, ab68459), HOPX mouse monoclonal antibody (1:50, Santa Cruz Inc., sc-398703), and mouse 
monoclonal antibody for human Ki67 (1:50, Dianova, DIA-670-P05). Immunostained lung sections were scanned 
with a scanning device (Nano-Zoomer, Hamamatsu), and examined histopathologically using the ‘NDP.view2 
software’ at 200×, 400× and 800× original magnification. IHC for mentioned antibodies was undertaken in 12 
IPF- and 5 control-donor lung samples.
Western blotting. Western blotting was performed as previously described20
In silico analysis. HOPX expression was evaluated using the microarray dataset from Lung Genomics 
Research Consortium (LGRC) and the dataset from the previous reports21.
Data presentation and statistical analysis. Unless otherwise described, all data are presented as 
means ± standard deviation (SD). Statistical analyses were performed using the Graph Pad Prism 6 software.
For the statistical comparison of differences between two groups, the unpaired t-test was applied. For the 
statistical comparison of differences between three groups, one-way ANOVA with Bonferroni’s multiple compar-
isons test as post-test was applied. Statistical significance was defined as p < 0.05.
Data availability. The datasets analyzed during the current study are available from the corresponding 
author on reasonable request.
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